Squamous cervical cancers are sensitive to VEGF inhibition, and the monoclonal antibody VEGF inhibitor bevacizumab is effective in combination with chemotherapy in a subset of patients with metastatic disease [5]. The gene discussed is VEGFA; the disease is cervical carcinoma.